The innovative pharmaceutical industry of Hungary is one of the first to implement new rules of conduct that are being introduced across Europe.
These rules of ethics are contained in the newly-approved Code of Practice of the Association of Innovative Pharmaceutical Manufacturers (AIPM) in Hungary.
The new regulations increase transparency of relationships between the pharmaceutical industry and healthcare organizations, providers and patient organizations to an even higher level. The AIPM hopes that other domestic pharmaceutical industry players will also join the initiative.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze